HOSPITALIZED WITH COVID 19. THE STATE'S POSITIVITY RATE IS NOW ABOVE 12 PERCENT 12
PERCENT.
BUT SOME GOOD NEWS ON
THE HORIZON ABOUT ANOTHER
VACCCINE CANDIDATE WITH MADONNA
ANNOUNCING TODAY IT'S VACCCINE
IT'S ALMOST 95 PERCENT
EFFECTIVE IN EARLY TRIALS AT
PREVENTING COVID 19.
SO LET'S TALK TO OUR
NINE HEALTH EXPERT DR. PAUL
COLEY BREAKING DOWN THE SCIENCE
AND THE IMPLICATIONS FOR
THE POTENTIAL AS WE HOPE TO END
THAT PANDEMIC.
DR. KOHLI, THIS EXCITING NEWS.
SOME THOUGH ARE HESITATING TO
GET THAT VACCINE.
MANY REASONS SOME PEOPLE THINK
IT MIGHT ACTUALLY BE SOMETHING
THAT GIVES YOU COVERED WONDER
IF THAT'S SIMILAR TO THE MYTH
THAT WE HAVE FOR MANY THAT
THE FLU VACCINE ACTUALLY CAN
GIVE YOU THE FLU.
YEAH, I'M REALLY GLAD YOU ASKED
THIS QUESTION BECAUSE YOU'RE
RIGHT, ABOUT 40 PERCENT
OF AMERICANS ARE WORRIED THAT
THEY MIGHT CONTRACT COLBERT
FROM THE VACCINE.
BUT TOM, THAT'S SCIENTIFICALLY
IMPOSSIBLE TO DO AND THAT'S
WHAT'S SO GREAT ABOUT THESE
VACCINES BECAUSE THEY'RE
DESIGNED THEIR MESSENGER RNA OR
M RNA VACCINES WHICH
ESSENTIALLY MEANS THAT YOU'RE
JUST GETTING INJECTED WITH A
SMALL LITTLE PIECE OF THAT
GENETIC BLUEPRINT OF JUST A
PART OF THE VIRUS.
THE SPIKE PROTEIN, THE PROTEIN
THAT THE VIRUS USES TO GET
INSIDE CELLS.
SO YOU'RE DEFINITELY NOT
GETTING THE WHOLE VIRUS
INACTIVATED OR ACTIVATED IN ANY
FORM.
YOU'RE JUST GETTING ESSENTIALLY
JUST A LITTLE PIECE OF ITS
GENETIC BLUEPRINT AND THEN YOUR
IMMUNE SYSTEM CAN LEARN HOW TO
FIGHT IT.
BUT TOM, KEEP IN MIND THAT
BASED ON THE PRELIMINARY
CLINICAL TRIALS DATA PEOPLE DO
HAVE YOU KNOW, MOST OF MALAYS
ARTHRALGIA AS FATIGUE FEVER
OCCURRING AFTER THE INJECTION.
BUT THAT IS NOT THEM GETTING
SICK WITH A VIRUS THAT IS THEIR
IMMUNE SYSTEM RUBBING UP AND
LEARNING HOW TO FIGHT
THE INFECTION.
IT'S BEEN A VERY INTERESTING
WEEK.
I THINK WHEN I WAS LEARNING
ABOUT MESSENGER RNA IT HAD JUST
BEEN INVENTED.
IT WAS A WHILE AGO I DIDN'T GET
IT THEN BUT NOW IT REALLY IS
SOMETHING THAT WE'RE STARTING
TO LEARN QUITE A BIT ABOUT IT
FOR ALL OF US FOR REGULAR
PEOPLE.
SO LET'S TALK ABOUT THE TWO
VACCINES.
PFIZER COMES OUT A WEEK AGO
MADDERN AND NOW IS THERE A BIG
DIFFERENCE?
IS THERE AN ADVANTAGE ONE OVER
THE OTHER?
YOU KNOW, THERE ARE A LOT
OF SIMILARITIES BETWEEN THESE
TWO FRONT RUNNER CANDIDATES.
SO I SEE YOU SAID THAT BOTH
MESSENGER RNA VACCINES SO THEY
WORKED BY SIMILAR TECHNOLOGY
LIKE WE DISCUSSED.
THEY'RE BOTH GIVEN IN TWO
DOSES.
YOU KNOW, AND THEY'RE BOTH
ABOUT SIMILAR EFFICACY.
SO THE PFIZER VACCINE WAS ABOUT
90 PERCENT AS WE TALKED ABOUT
LAST WEEK.
THIS ONE'S ABOUT NINETY FOUR
POINT FIVE PERCENT.
BUT WHERE THE DIFFERENCE REALLY
COMES IN WITH A MATURE ENOUGH
VACCINE HAVING A HUGE ADVANTAGE
IN MY OPINION OVER THE PFIZER
VACCINE IS HOW IT'S STORED AND
HOW IT'S THOUGHT.
SO THE STORAGE FOR THIS VACCINE
IS MINUS 20 DEGREES CELSIUS
WHICH IS MINUS FOUR DEGREES
FAHRENHEIT AS OPPOSED TO
THE PFIZER VACCCINE WHICH IS
MINUS 70 DEGREES CELSIUS.
AND THEN ONCE YOU THOUGHT, TOM,
THE PFIZER VACCINE IS ONLY
STABLE FRIDGE FOR FIVE DAYS AS
OPPOSED TO THE MADONA VACCINE
WHICH IS STABLE FOR 30 DAYS IN
THE FRIDGE.
NOW THINK ABOUT
THE IMPLICATIONS OF THIS
BECAUSE THE WORLD HEALTH
ORGANIZATION ESTIMATES THAT
GREATER THAN HALF OF THE
VACCINES THAT ARE DISTRIBUTED
GO BAD BECAUSE THEY'RE NOT
STORED PROPERLY AND THE MRI AND
VACCINES AS WE'VE TALKED ABOUT
ARE ESSENTIALLY VERY SENSITIVE
TO BEING STORED AT EXTREMELY
COLD TEMPERATURES BECAUSE THAT
MRV CAN DEGRADE VERY QUICKLY.
SO YOU HAVE THIS COLD CHAIN
THAT YOU HAVE TO MAINTAIN.
SO THE MADONNA VACCINE REALLY
DOES INTRODUCE A VERY EXCITING
NEW DEVELOPMENT BECAUSE IT CAN
BE STORED AT LESS COLD
TEMPERATURES AND IT CAN BE KEPT
IN THE FRIDGE WHICH A LOT
OF PLACES HAVE LIKE DOCTORS'
OFFICES FOR UP TO 30 DAYS.
WE'RE TALKING ABOUT 90 PERCENT
AND 94 PERCENT EFFICACY.
BUT WHAT ABOUT SAFETY?
WHAT IS IT YOU WANT TO KNOW
BEFORE YOU'RE READY TO GET THIS
VACCINE FOR YOURSELF TO GIVE TO
YOUR FAMILY OR FRIENDS OR
PATIENTS?
YEAH.
PATIENTS? YEAH. MY TOP CONCERN REALLY IS
THE SAFETY.
SO IN THE PRESS RELEASE
THE DERNA HAS RELEASED A LITTLE
BIT OF PRELIMINARY INFORMATION
ABOUT SAFETY AND SO FAR IT'S
JUST BEEN THE USUAL THINGS THAT
WE EXPECT IN A VACCCINE
INJECTION SITE REACTIONS,
MUSCLE ACHES AND PAINS, FEVERS
LIKE WE DISCUSSED HEADACHE
FATIGUE.
SO NOTHING ALARMING THERE.
BUT I DO HAVE TO SAY THAT THIS
IS A BRAND NEW VACCCINE
TECHNOLOGY THAT MARNAY HAS NOT
BEEN USED IN A VACCCINE BEFORE
AND LIKLEY IT IS GOING TO TAKE
SEVERAL MILLION DOSES BEFORE WE
START TO SEE SOME OF THOSE RARE
SAFETY SIDE EFFECTS EMERGE.
SO IT'S GOING TO NEED REALLY
CLOSE SURVEILLANCE EVEN AFTER
ITS RELEASE.
BUT THE SECOND QUESTION, TOM,
THAT STILL REMAINS ON MY MIND
IS REGARDING EFFICACY.
SO WE'RE SEEING THESE DRAMATIC
NUMBERS AND NOW THAT WE'VE SEEN
THEM IN TWO DIFFERENT TRIALS,
THEY'RE A LITTLE BIT MORE
LIKELY TO BE TRUE.
BUT KEEP IN MIND THAT IT'S VERY
SMALL NUMBERS THAT WE'RE
TALKING ABOUT.
SO
THIS
THIS MAJANO TRIAL, 90 PEOPLE IN THE PLACEBO ARM GOT THE INFECTION AND ONLY FIVE
PEOPLE IN THE VACCCINE ARM.
SO TOTAL OF NINETY FIVE
INFECTION'S OUT OF THIRTY
THOUSAND PEOPLE.
AND THE WAY THE TRIAL WAS
DESIGNED, YOU REALLY NEEDED TO
HIT AT LEAST ONE HUNDRED AND
SIXTY FIVE INFECTIONS IN ORDER
TO KNOW THAT THIS DIDN'T JUST
HAPPEN BY STATISTICAL
PROBABILITY AND WAS A REAL